Evotec and Novo Nordisk Expand LAB eN² Program and Select First Projects to Advance Cardiometabolic Research

(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases. The projects, from Boston University, Harvard University in collaboration with Mass General Brigham, … Read the full press release →